Lung Health for All: Chronic Obstructive Lung Disease and World Lung Day 2022
“Lung Health for All” is the key theme of World Lung Day 2022 (September 25). The day aims to highlight the global burden of the major respiratory diseases and the impact of coronavirus disease (COVID-19), with a focus on low- and middle-income countries (LMIC). Key messages for the day are the importance of early detection and reduction of inequalities. These align well with the objectives Global Initiative for Chronic Obstructive Lung Disease (GOLD) of improving the diagnosis and management of chronic obstructive pulmonary disease (COPD) around the world. COPD affects 1 in 10 of the adult global population and is one of the three commonest causes of death worldwide. It is also a major cause of the global inequalities in health and is more prevalent where such inequalities are more extreme.
Puedes leer el artículo completo aquí: https://www.atsjournals.org/doi/full/10.1164/rccm.202207-1407ED?role=tab
Autores: David M. G. Halpin, Claus F. Vogelmeier and Alvar Agusti for the Global Initiative for Chronic Obstructive Lung Disease.
Noticias relacionadas
Diagnostic Metabolomic Profiling of COPD as Potential Biomarkers in Older and Younger Patients
Study identifies 10-metabolite panel distinguishing COPD from healthy subjects with ~90% accuracy, highlighting lipid metabolism dysregulation and offering new diagnostic insights.
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Discover the latest advances now pipeline new COPD treatments pipeline, from monoclonal antibodies to emerging therapies, and future opportunities in clinical development.
Different Immune Infiltrate in Idiopathic Pulmonary Fibrosis Patients With Stable and Progressive Disease
Research on idiopathic pulmonary fibrosis reveals how immune infiltrate differences in early stages influence disease progression. Study highlights the role of B cells, T cells, and NK cells as potential biomarkers.
Más artículos
COPD
- 759578·Alberto Papi et Al.-Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY
- 759785·Richard Beasley et Al – Prevalence, Diagnostic Utility and Associated Characteristics of Bronchodilator Responsiveness
- 759788·Alvar Agustí, Rod Hughes, Eleni Rapsomaki, Barry Make, Ricardo Del Olmo, Alberto Papi, David Price, Laura Benton, Stefan Franzen, Jørgen Vestbo, Hana Mullerova – The many faces of COPD in real life: a longitudinal analysis of the NOVELTY cohort
- 759883·Alberto Papi, Rosa Faner, Ian Pavord, Federico Baraldi, Vanessa M McDonald, Mike Thomas, Marc Miravitlles, Nicholas Roche, Alvar Agustí. – From treatable traits to GETomics in airway disease: moving towards clinical practice
- 768799·Surya P Bhatt Richard Casaburi Alvar Agusti et Al. Chronic obstructive pulmonary disease: hiding in plain sight, a Statement from the COPD Foundation Medical and Scientific Advisory Committee
Recuerda que puedes acceder a varios enlaces a artículos dentro de la categoría EPOC en esta web. También puedes acceder otros enlaces en el Listado de Artículos de la Cátedra de Salud Respiratoria.
Imagen obtenida en el artículo original.